Inflammatory Myositis Market: Epidemiology, Therapies, Companies, DelveInsight | CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfi

Inflammatory myositis emerging therapies, such as Dazukibart (PF-06823859), and others, are expected to boost the Inflammatory myositis Market in the upcoming years.

DelveInsight has launched a new report on "Inflammatory myositis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Inflammatory myositis, historical and forecasted epidemiology as well as the Inflammatory myositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the inflammatory myositis market report @ https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Inflammatory Myositis Market Report:

The total market size of Inflammatory myositis in the 7MM is approximately USD 589 million in 2023 and is projected to increase during the forecast period (2024-2034)
In 2023, the U.S. market for inflammatory myositis emerged as a key player among the seven major markets (7MM), reaching a notable valuation of USD 301 million. This figure reflects strong current demand and emphasizes the considerable growth potential in this field.
Several promising therapies, including PF-06823859 and Brepocitinib, are anticipated to enter the market during the 2020-2034 forecast period.
The inflammatory myositis therapeutics market is set to grow at a robust pace, with an estimated compound annual growth rate (CAGR) of around 11.7% across the 7MM. This growth is driven by increasing demand for innovative treatment solutions and a rise in investment focused on this serious condition.
In June 2024, Cabaletta Pharmaceuticals reported encouraging preliminary clinical data from the first participant in the immune-mediated necrotizing myopathy (IMNM) cohort of its Phase I/II RESET-Myositis trial. The data, reflecting a three-month follow-up, were presented at a high-profile satellite symposium during the EULAR 2024 Congress, highlighting the promise of Cabaletta's novel therapeutic approach. Patient enrollment in the RESET-Myositis trial is ongoing, with more comprehensive clinical results expected in late 2024. This research marks a pivotal development in IMNM treatment and underscores Cabaletta's leadership in advancing innovative therapies for this complex disease.
Key Inflammatory myositis companies such as CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences, and others are evaluating new drugs for Inflammatory myositis to improve the treatment landscape.
Promising Inflammatory myositis therapies include Dazukibart (PF-06823859), and others.

Inflammatory Myositis Overview

Myositis refers to inflammation of the muscles and is commonly linked with a group of inflammatory muscle diseases, including polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). While *myositis* specifically involves inflammation, *myopathy* is a broader term encompassing any disease or disorder of the muscles, including but not limited to myositis.

This rare condition can impact not only the muscles but also various other organs, often resulting in significant reductions in quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases in which the immune system mistakenly attacks healthy muscle tissue. Dermatomyositis and polymyositis are the most frequently occurring types within this group.

Inflammatory Myositis Market Outlook

The treatment of inflammatory myositis has progressed over time, typically involving a combination of immunosuppressive therapies-such as corticosteroids, DMARDs, and biologics-alongside physical therapy and supportive care. Despite these advancements, there remains a need for more effective and targeted treatments with fewer side effects. Emerging therapies, including biologics and small-molecule inhibitors, hold promise for improving patient outcomes and shaping future market trends.

Intravenous immunoglobulin (IVIg) has shown effectiveness as a first-line monotherapy in about 50% of patients with idiopathic inflammatory myopathies, often yielding results within three weeks for responders. For cases unresponsive to standard treatments like corticosteroids, immunosuppressants, and IVIg, intravenous cyclophosphamide may be considered as a fourth-line option, though it carries significant risks and is reserved for severe, treatment-resistant cases. Treatment strategies are typically tailored to each patient, based on disease severity, treatment response, and clinical judgment.

Discover how the inflammatory myositis market is rising in the coming years @ https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Inflammatory Myositis Emerging Drugs
Dazukibart (PF-06823859): Pfizer

Scope of the Inflammatory Myositis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Inflammatory Myositis Companies: CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences, and others
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), and others
Inflammatory myositis Therapeutic Assessment: Inflammatory myositis current marketed and Inflammatory myositis emerging therapies
Inflammatory myositis Market Dynamics: Inflammatory myositis market drivers and Inflammatory myositis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Inflammatory myositis Unmet Needs, KOL's views, Analyst's views, Inflammatory myositis Market Access and Reimbursement

To know what's more in our inflammatory myositis report, visit https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Inflammatory Myositis Market Report:
Inflammatory myositis market report covers a descriptive overview and comprehensive insight of the Inflammatory myositis Epidemiology and Inflammatory myositis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Inflammatory myositis market report provides insights into the current and emerging therapies.
The inflammatory myositis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Inflammatory myositis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Inflammatory myositis market.

Got queries? Click here to know more about the inflammatory myositis market Landscape https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Inflammatory myositis Patient Share (%) Overview at a Glance
5. Inflammatory myositis Market Overview at a Glance
6. Inflammatory myositis Disease Background and Overview
7. Inflammatory myositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Inflammatory myositis
9. Inflammatory myositis Current Treatment and Medical Practices
10. Unmet Needs
11. Inflammatory myositis Emerging Therapies
12. Inflammatory myositis Market Outlook
13. Country-Wise Inflammatory myositis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Inflammatory myositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Inflammatory myositis Market Outlook 2034 https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Inflammatory myositis Pipeline Insights, DelveInsight

"Inflammatory myositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inflammatory myositis market. A detailed picture of the Inflammatory myositis pipeline landscape is provided, which includes the disease overview and Inflammatory myositis treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.